Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Cell Therapy for Cancers
share announcement

Cell Therapy for Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (20 April 2022) | Viewed by 21324

Special Issue Editor

Dr. Veronique Decot

E-Mail Website
Guest Editor
CHRU de Nancy, Unité de Thérapie Cellulaire Etbanque de Tissus, 54500 Vandoeuvre-lès-Nancy, France
Interests: immunotherapy; natural killer cells; gd T cells

Special Issue Information

Dear Colleagues,

Cell therapy is part of the therapeutic arsenal of cancer treatment and has become a major therapeutic option in hematology, with the transplant of hematopoietic stem cells. It is now taking a new turn due to better knowledge of the functioning of immune cells and has benefited from renewed interest with the development of CAR T cells. Since their arrival on the market, other cells have enter the race, including CAR NK cells, CAR macrophages or CAR T regs, all with their own advantages and inconveniences. In this Special Issue, we wish to take stock of the developing and available cell therapies indicated in the treatment of hemopathies and solid tumors. We will discuss their regulatory status, their method of development and the criteria for evaluating their efficacy in vitro and in vivo.

Dr. Véronique Décot
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cell therapy
  • cell engineering
  • potency assays
  • regulatory requirements
  • solid tumors
  • haematological malignancies
  • advanced therapeutic medicinal products

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

22 pages, 1305 KiB  
Review
Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy
by Derek Lee, Carl J. Rosenthal, Natalie E. Penn, Zachary Spencer Dunn, Yang Zhou and Lili Yang
Cancers 2022, 14(12), 3005; https://doi.org/10.3390/cancers14123005 - 18 Jun 2022
Cited by 19 | Viewed by 5163
Abstract
Gamma delta (γδ) T cells are a minor population of T cells that share adaptive and innate immune properties. In contrast to MHC-restricted alpha beta (αβ) T cells, γδ T cells are activated in an MHC-independent manner, making them ideal candidates for developing [...] Read more.
Gamma delta (γδ) T cells are a minor population of T cells that share adaptive and innate immune properties. In contrast to MHC-restricted alpha beta (αβ) T cells, γδ T cells are activated in an MHC-independent manner, making them ideal candidates for developing allogeneic, off-the-shelf cell-based immunotherapies. As the field of cancer immunotherapy progresses rapidly, different subsets of γδ T cells have been explored. In addition, γδ T cells can be engineered using different gene editing technologies that augment their tumor recognition abilities and antitumor functions. In this review, we outline the unique features of different subsets of human γδ T cells and their antitumor properties. We also summarize the past and the ongoing pre-clinical studies and clinical trials utilizing γδ T cell-based cancer immunotherapy. Full article
(This article belongs to the Special Issue Cell Therapy for Cancers)
►▼ Show Figures

Figure 1

29 pages, 1779 KiB  
Review
Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
by Yang Zhou, Miao Li, Kuangyi Zhou, James Brown, Tasha Tsao, Xinjian Cen, Tiffany Husman, Aarushi Bajpai, Zachary Spencer Dunn and Lili Yang
Cancers 2022, 14(9), 2266; https://doi.org/10.3390/cancers14092266 - 01 May 2022
Cited by 23 | Viewed by 9382
Abstract
Cell-based immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has revolutionized the treatment of hematological malignancies, especially in patients who are refractory to other therapies. However, there are critical obstacles that hinder the widespread clinical applications of current autologous therapies, such [...] Read more.
Cell-based immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has revolutionized the treatment of hematological malignancies, especially in patients who are refractory to other therapies. However, there are critical obstacles that hinder the widespread clinical applications of current autologous therapies, such as high cost, challenging large-scale manufacturing, and inaccessibility to the therapy for lymphopenia patients. Therefore, it is in great demand to generate the universal off-the-shelf cell products with significant scalability. Human induced pluripotent stem cells (iPSCs) provide an “unlimited supply” for cell therapy because of their unique self-renewal properties and the capacity to be genetically engineered. iPSCs can be differentiated into different immune cells, such as T cells, natural killer (NK) cells, invariant natural killer T (iNKT) cells, gamma delta T (γδ T), mucosal-associated invariant T (MAIT) cells, and macrophages (Mφs). In this review, we describe iPSC-based allogeneic cell therapy, the different culture methods of generating iPSC-derived immune cells (e.g., iPSC-T, iPSC-NK, iPSC-iNKT, iPSC-γδT, iPSC-MAIT and iPSC-Mφ), as well as the recent advances in iPSC-T and iPSC-NK cell therapies, particularly in combinations with CAR-engineering. We also discuss the current challenges and the future perspectives in this field towards the foreseeable applications of iPSC-based immune therapy. Full article
(This article belongs to the Special Issue Cell Therapy for Cancers)
►▼ Show Figures

Figure 1

Other

Jump to: Review

18 pages, 2749 KiB  
Systematic Review
Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input
by Valentine Wang, Mélanie Gauthier, Véronique Decot, Loïc Reppel and Danièle Bensoussan
Cancers 2023, 15(4), 1003; https://doi.org/10.3390/cancers15041003 - 04 Feb 2023
Cited by 15 | Viewed by 5880
Abstract
The development of Chimeric Antigen Receptor T cells therapy initiated by the United States and China is still currently led by these two countries with a high number of clinical trials, with Europe lagging in launching its first trials. In this systematic review, [...] Read more.
The development of Chimeric Antigen Receptor T cells therapy initiated by the United States and China is still currently led by these two countries with a high number of clinical trials, with Europe lagging in launching its first trials. In this systematic review, we wanted to establish an overview of the production of CAR-T cells in clinical trials around the world, and to understand the causes of this delay in Europe. We particularly focused on the academic centers that are at the heart of research and development of this therapy. We counted 1087 CAR-T cells clinical trials on ClinicalTrials.gov (Research registry ID: reviewregistry1542) on the date of 25 January 2023. We performed a global analysis, before analyzing the 58 European trials, 34 of which sponsored by academic centers. Collaboration between an academic and an industrial player seems to be necessary for the successful development and application for marketing authorization of a CAR-T cell, and this collaboration is still cruelly lacking in European trials, unlike in the leading countries. Europe, still far behind the two leading countries, is trying to establish measures to lighten the regulations surrounding ATMPs and to encourage, through the addition of fundings, clinical trials involving these treatments. Full article
(This article belongs to the Special Issue Cell Therapy for Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop